{
    "name": "capmatinib",
    "comment": "Rx",
    "other_names": [
        "Tabrecta"
    ],
    "classes": [
        "MET Tyrosine Kinase Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/tabrecta-capmatinib-4000068",
    "pregnancy": {
        "common": [
            "Based on animal studies and its mechanism of action, fetal harm may occur when administered to pregnant females",
            "No available data on use in pregnant females",
            "Verify pregnancy status for females of reproductive potential before starting treatment"
        ],
        "specific": [
            {
                "type": "Contraception",
                "description": [
                    "Females of reproductive potential: Use effective contraception during treatment and for 1 week after final dose",
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 1 week after final dose"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Oral administration to pregnant rats and rabbits during organogenesis resulted in malformations at maternal exposures less than the human exposure based on AUC at the 400 mg BID clinical dose "
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "No data available on the presence of capmatinib or its metabolites in either human or animal milk or its effects on breastfeeding, or on milk production",
            "Advise females not to breastfeed during treatment and for 1 week after final dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "ILD/pneumonitis, which can be fatal, occurred during clinical trials; monitor for new or worsening pulmonary symptoms indicative of ILD/pneumonitis",
                "Hepatotoxicity occurred; monitor liver function tests (including ALT, AST, and total bilirubin) before initiation, every 2 weeks during the first 3 months of treatment, and then once monthly or as clinically indicated, with more frequent testing in patients who develop increased transaminases or bilirubin",
                "Elevations in amylase and lipase levels occurred in patients receiving therapy; monitor amylase and lipase at baseline and regularly during treatment; based on severity of adverse drug reaction, temporarily withhold, dose reduce, or permanently discontinue therapy",
                "Serious hypersensitivity reactions reported with use; signs and symptoms of hypersensitivity included pyrexia, chills, pruritus, rash, decreased blood pressure, nausea, and vomiting; based on severity of adverse reaction, temporarily withhold or permanently discontinue therapy",
                "May cause photosensitivity reactions; advise patients to limit direct ultraviolet exposure; limit direct ultraviolet exposure by using sunscreen or protective clothing during treatment",
                "Fetal harm may occur"
            ],
            "specific": [
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Capmatinib is a CYP3A4 substrate and inhibits CYP1A2, P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), MATE 1, and MATE2K",
                        "Strong CYP3A Inhibitors",
                        "Coadministration with a strong CYP3A inhibitor increased capmatinib exposure, which may increase the incidence and severity of adverse reactions of capmatinib",
                        "Closely monitor for adverse reactions",
                        "Strong and moderate CYP3A inducers ",
                        "Avoid coadministration",
                        "Concomitant use with capmatinib a strong or moderate CYP3A inducer decreased capmatinib exposure and efficacy ",
                        "Substrates of CYP1A2, P-gp, BCRP, MATE1 or MATE2K ",
                        "Coadministration with CYP1A2, P-gp, BCRP, MATE1 or MATE2K substrates increased the exposure and adverse reactions of these substrates ",
                        "If coadministration unavoidable, reduce dose of CYP1A2, P-gp, BCRP, MATE1 or MATE2K substrate in accordance with the approved prescribing information"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "enzalutamide will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "lorlatinib will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mifepristone",
            "description": {
                "common": "mifepristone will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "berotralstat",
            "description": {
                "common": "capmatinib increases levels of berotralstat by Other (see comment). Modify Therapy/Monitor Closely. \nComment: Reduced dose of berotralstat (a BCRP substrate) to 110 mg/day when coadministered with BCRP inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "ceritinib will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "idelalisib",
            "description": {
                "common": "idelalisib will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "ivosidenib will decrease the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ribociclib",
            "description": {
                "common": "ribociclib will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selexipag",
            "description": {
                "common": "capmatinib will increase the level or effect of selexipag by  Other (see comment). Use Caution/Monitor. Selexipag is a ABCG2 (BCRP) substrate. Monitor selexipag for increased pharmacologic or adverse effects when coadministered with ABCG2 (BCRP) inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "larotrectinib will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Decreased albumin",
            "percent": "68"
        },
        {
            "name": "Increased creatinine",
            "percent": "62"
        },
        {
            "name": "Peripheral edema",
            "percent": "52"
        },
        {
            "name": "Nausea",
            "percent": "44"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "44"
        },
        {
            "name": "Increased ALT",
            "percent": "37"
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": "32"
        },
        {
            "name": "Fatigue",
            "percent": "32"
        },
        {
            "name": "Increased amylase",
            "percent": "31"
        },
        {
            "name": "Increased gamma",
            "percent": "29"
        },
        {
            "name": "glutamyltransferase",
            "percent": "28"
        },
        {
            "name": "GGT",
            "percent": "26"
        },
        {
            "name": "Vomiting",
            "percent": "25"
        },
        {
            "name": "Increased lipase",
            "percent": "24"
        },
        {
            "name": "Increased AST",
            "percent": "24"
        },
        {
            "name": "Dyspnea",
            "percent": "23"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": "23"
        },
        {
            "name": "Decreased sodium",
            "percent": "23"
        },
        {
            "name": "Decreased phosphate",
            "percent": "23"
        },
        {
            "name": "Increased potassium",
            "percent": "21"
        },
        {
            "name": "Decreased leukocytes",
            "percent": "21"
        },
        {
            "name": "Decreased glucose",
            "percent": "18"
        },
        {
            "name": "Decreased appetite",
            "percent": "18"
        },
        {
            "name": "Constipation",
            "percent": "16"
        },
        {
            "name": "Diarrhea",
            "percent": "15"
        },
        {
            "name": "Cough",
            "percent": "14"
        },
        {
            "name": "Noncardiac chest pain",
            "percent": "14"
        },
        {
            "name": "Back pain",
            "percent": "14"
        },
        {
            "name": "Pyrexia",
            "percent": "10"
        },
        {
            "name": "Decreased lymphocytes",
            "percent": "10"
        },
        {
            "name": "Decreased weight",
            "percent": "9"
        },
        {
            "name": "Pruritus",
            "percent": "8"
        },
        {
            "name": "allergic and generalized",
            "percent": "8"
        },
        {
            "name": "ILD",
            "percent": "7"
        },
        {
            "name": "pneumonitis Cellulitis Acute kidney injury",
            "percent": "7"
        },
        {
            "name": "including renal failure",
            "percent": "7"
        },
        {
            "name": "Urticaria Acute pancreatitis",
            "percent": "6"
        },
        {
            "name": "Pruritus",
            "percent": "4.9"
        },
        {
            "name": "allergic and generalized",
            "percent": "4.4"
        },
        {
            "name": "ILD",
            "percent": "3.1"
        },
        {
            "name": "pneumonitis",
            "percent": "2.8"
        },
        {
            "name": "Cellulitis",
            "percent": "2.7"
        },
        {
            "name": "Acute kidney injury",
            "percent": "2.4"
        },
        {
            "name": "including renal failure",
            "percent": "2.1"
        },
        {
            "name": "Urticaria",
            "percent": "1.8"
        },
        {
            "name": "Acute pancreatitis",
            "percent": "0.9"
        },
        {
            "name": "Peripheral edema",
            "percent": "0.9"
        },
        {
            "name": "Fatigue",
            "percent": "0.9"
        },
        {
            "name": "Increased ALT",
            "percent": "0.9"
        },
        {
            "name": "Increased GGT",
            "percent": "0.6"
        },
        {
            "name": "Increased lipase",
            "percent": "0.6"
        },
        {
            "name": "Dyspnea",
            "percent": "0.6"
        },
        {
            "name": "Decreased sodium",
            "percent": "0.3"
        },
        {
            "name": "Increased AST",
            "percent": "0.3"
        },
        {
            "name": "Increased amylase",
            "percent": "0.3"
        },
        {
            "name": "Increased potassium",
            "percent": "0.3"
        },
        {
            "name": "Decreased hemoglobin",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Noncardiac chest pain",
            "percent": null
        },
        {
            "name": "Decreased albumin",
            "percent": null
        },
        {
            "name": "Back pain",
            "percent": null
        },
        {
            "name": "Constipation",
            "percent": null
        },
        {
            "name": "Decreased appetite",
            "percent": null
        },
        {
            "name": "Decreased leukocytes",
            "percent": null
        },
        {
            "name": "Pyrexia",
            "percent": null
        },
        {
            "name": "Decreased weight",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Decreased glucose",
            "percent": null
        },
        {
            "name": "Increased alkaline phosphatase",
            "percent": null
        },
        {
            "name": "Increased creatinine",
            "percent": null
        }
    ]
}